J&J Settles Talc Suits for $5.5B as Amazon Scales Back AI Models

Johnson and Johnson announced Monday it will pay an estimated 5.5 billion dollars to resolve around 76,000 lawsuits alleging its baby powder and other talc products caused ovarian cancer. The agreement covers claims consolidated in federal court in New Jersey along with related state cases and represents nearly all remaining talc litigation against the company.

The settlement requires acceptance by 95 percent of ovarian cancer claimants in state or federal court to take effect. Johnson and Johnson previously resolved most claims alleging its talc contained asbestos and caused mesothelioma. Plaintiffs' law firms involved in negotiations described the outcome as a reasonable end to a decade of courtroom conflict.

Company vice president of litigation Erik Haas stated the claims lacked merit and that Johnson and Johnson had prevailed in the vast majority of cases that reached trial. He explained the company chose settlement to achieve finality and redirect resources toward developing medicines and medical devices. Payments are scheduled to total 3 billion dollars in 2027 with additional amounts due in 2028. The total could rise if more claimants participate.

Attorney Chris Seeger, who represents roughly 2,500 clients with talc claims and helped shape the deal, confirmed the agreement. The litigation has spanned ten years and involved repeated challenges to scientific evidence linking talc to cancer. Johnson and Johnson has long maintained that its talc products are safe and asbestos-free based on extensive testing and regulatory reviews.

Such large-scale resolutions highlight how extended legal proceedings can impose heavy costs on businesses even when most individual cases fail. Companies often calculate that continued defense diverts management attention and capital from core operations. Johnson and Johnson signaled this dynamic in its statement that closure will allow greater focus on innovation that improves health outcomes.

The deal follows years of mixed trial results and appeals. Earlier attempts by the company to resolve claims through bankruptcy proceedings faced court setbacks. The current agreement avoids further uncertainty while providing structured payments over time.

Analysts note that plaintiff firms frequently pursue mass tort strategies to pressure defendants into settlements regardless of individual claim strength. In this instance the company emphasized that science and prior verdicts supported its position yet chose resolution to end the distraction. The outcome aligns with patterns seen in other industries where prolonged litigation serves as leverage rather than a test of evidence.

Johnson and Johnson expects the arrangement to clear the docket of nearly all remaining talc matters once the participation threshold is met. The company continues to face separate legal issues in other product areas but views the talc chapter as effectively closed.